Colorectal cancer remains the third most common cancer diagnosed globally, with approximately 30% classified as lower rectal cancer. In this context, Total Neoadjuvant Therapy (TNT) has emerged as a promising strategy for managing locally advanced rectal cancer. This approach combines radiotherapy and chemotherapy prior to surgery, demonstrating improved treatment outcomes. This event will explore the current status and future directions of TNT clinical trials across various countries, along with institutional strategies for adopting TNT. Additionally, we will discuss effective surgical management following preoperative therapy, emphasizing the safe and appropriate use of medical devices.
Colorectal cancer remains the third most common cancer diagnosed globally, with approximately 30% classified as lower rectal cancer. In this context, Total Neoadjuvant Therapy (TNT) has emerged as a promising strategy for managing locally advanced rectal cancer. This approach combines radiotherapy and chemotherapy prior to surgery, demonstrating improved treatment outcomes.
This event will explore the current status and future directions of TNT clinical trials across various countries, along with institutional strategies for adopting TNT. Additionally, we will discuss effective surgical management following preoperative therapy, emphasizing the safe and appropriate use of medical devices.
PROGRAM:
Clinical Background
Welcome & Introduction - Dr. Rodrigo Perez (Brazil)
The Challenge for a Novel Practical Strategy for Locally Advanced Rectal Cancer to Overcome the Paradox by Total Neoadjuvant Therapy and Nonoperative Management - Dr. Atsushi Ogura (Japan)
Total Neoadjuvant Therapy for Local Advanced Rectal Cancer - Dr. Ziqiang Wang (China)
Panel Discussion - All faculty moderated by Dr. Rodrigo Perez (Brazil)
Closing Remarks - Dr. Rodrigo Perez (Brazil)
.jpg)
Share it with your network and help spread clinical knowledge.
